focus -WSS

focus

author：entertainment 2025-08-25 08:45:37 - browse：2

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Insurer loopholes limit power of law against surprise medical bills

WSS

Adam's Biotech Scorecard: Do Sarepta's exon

Do more moles mean more problems? Not so, says new study

Bird flu in dairy cattle: New measures to control spread to humans

Drug companies' payments and gifts affect physicians' prescribing

Scientists uncover potential path to treating deadly childhood tumor

David Sabatini, ex

explore

focus

focus

Affirmative action in medical school literally saved lives

Startling documents reveal new facets of Sacklers' opioid empire

Walensky prepares to leave CDC — and Congress — behind

Scientists uncover potential path to treating deadly childhood tumor

The cancer drug shortage isn’t new — and neither are the solutions

Bird flu in dairy cattle: New measures to control spread to humans

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Stigma and the return of syphilis

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

hotspot

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Harvard scientists, with Google, unveil the most detailed brain map ever

Addiction doctors spar with methadone clinics over legislation

People with mental disorders often marry others with same

Akili, maker of video game for ADHD, to be acquired for 34 million

Scientists successfully use ultrasound imaging to map brain activity

hotspot

focus

focus

explore